
Journey Colab
Developing psychedelic-based treatments for addiction, starting with a synthetic version of mescaline, a psychedelic compound, for use alongside talk therapy to treat alcohol use disorder.
Employees
Enterprise value
$48—72m
Authorizing premium user...